BREAKING NEWS Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) in previously treated advanced neuroendocrine tumours. Decision expected Q3. Hopefully @MHRAgovuk will be seeking their own approval/indication change https://t.co/Y8Qn6sXGw9